ZymoGenetics Furthers Bristol's "Multi-Pronged" Approach To HCV, Sigal Says

R&D President Sigal talks about how the acquisition of ZymoGenetics fits into Bristol's research strategy in his first public comments to investors since March.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet